- Home
- DTSS vs SYBX Comparison
DTSS vs SYBX Comparison
Compare DTSS & SYBX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DTSS
- SYBX
- Stock Information
- Founded
- DTSS 2014
- SYBX N/A
- Country
- DTSS China
- SYBX United States
- Employees
- DTSS N/A
- SYBX N/A
- Industry
- DTSS Computer Software: Prepackaged Software
- SYBX Biotechnology: Pharmaceutical Preparations
- Sector
- DTSS Technology
- SYBX Health Care
- Exchange
- DTSS Nasdaq
- SYBX Nasdaq
- Market Cap
- DTSS 16.5M
- SYBX 16.4M
- IPO Year
- DTSS N/A
- SYBX N/A
- Fundamental
- Price
- DTSS $1.91
- SYBX $1.46
- Analyst Decision
- DTSS
- SYBX
- Analyst Count
- DTSS 0
- SYBX 0
- Target Price
- DTSS N/A
- SYBX N/A
- AVG Volume (30 Days)
- DTSS 49.4K
- SYBX 53.6K
- Earning Date
- DTSS 09-25-2025
- SYBX 08-07-2025
- Dividend Yield
- DTSS N/A
- SYBX N/A
- EPS Growth
- DTSS N/A
- SYBX N/A
- EPS
- DTSS N/A
- SYBX N/A
- Revenue
- DTSS $56,255,129.00
- SYBX N/A
- Revenue This Year
- DTSS N/A
- SYBX N/A
- Revenue Next Year
- DTSS N/A
- SYBX N/A
- P/E Ratio
- DTSS N/A
- SYBX N/A
- Revenue Growth
- DTSS 144.20
- SYBX N/A
- 52 Week Low
- DTSS $1.63
- SYBX $0.90
- 52 Week High
- DTSS $3.55
- SYBX $1.96
- Technical
- Relative Strength Index (RSI)
- DTSS 48.36
- SYBX 52.54
- Support Level
- DTSS $1.80
- SYBX $1.33
- Resistance Level
- DTSS $2.00
- SYBX $1.67
- Average True Range (ATR)
- DTSS 0.09
- SYBX 0.12
- MACD
- DTSS 0.01
- SYBX -0.01
- Stochastic Oscillator
- DTSS 62.50
- SYBX 38.24
About DTSS Datasea Inc.
Datasea Inc is a technology company. Its offers provides acoustic business services (focusing on high-tech acoustic technologies and applications such as ultrasound, infrasound, and Schumann resonance), 5G application services (5G AI multimodal digital business), and other products and services to various corporate and individual customers. The business activity of the group functions through China.
About SYBX Synlogic Inc.
Synlogic Inc is a biopharmaceutical company focuses on rare metabolic disorders, with a lead program in phenylketonuria (PKU) and homocystinuria (HCU). The company's pipeline includes therapeutics for enteric hyperoxaluria, gout, and cystinuria. Using a proprietary approach, the company engineer GI-restricted, oral medicines from well-characterized probiotics. These drug candidates target specific biological pathways, leveraging Escherichia coli Nissle 1917 for consistency and safety. Engineered to be non-colonizing and reversible, the company offer oral administration, simplifying shipping and storage. The company operates in one segment-discovery and development of Synthetic Biotics-pioneering transformative treatments for serious diseases.